Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

Modern Pathology

Volumn 31, Issue 6, 2018, Pages 965-973

  Zen, Yoh ^a   Yeh, Matthew M ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IPILIMUMAB; METHOTREXATE; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISOLONE; URSODEOXYCHOLIC ACID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADOLESCENT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT INJURY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER TOXICITY; MALE; MEDICAL RECORD; MELANOMA; MONOTHERAPY; PLASMACYTOSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TONGUE CARCINOMA; TOXIC HEPATITIS; TREATMENT DURATION; ADULT; IMMUNOTHERAPY; LIVER; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, SQUAMOUS CELL; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOTHERAPY; LIVER; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TONGUE NEOPLASMS; YOUNG ADULT;

EID: 85041624633     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/s41379-018-0013-y     Document Type: Article

References (29)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-82.
2. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30.
4. Melosky B, Chu Q, Juergens R, et al. Pointed progress in secondline advanced non-small-cell lung cancer: The rapidly evolving field of checkpoint inhibition. J Clin Oncol. 2016;34:1676-88.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
6. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.
7. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase ii trial. J Clin Oncol. 2015;33:1430-7.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
9. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275-83.
10. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33.
11. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
12. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic Tlymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614-27.
13. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-25.
14. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4 (+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50.
15. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015-29.
16. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
17. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS ONE. 2016;11: E0160221.
18. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: Imaging and clinicopathologic findings. Invest New Drugs. 2013;31:1071-7.
19. Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated Hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075-84.
20. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233-40.
21. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-76.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.
23. Simonelli M, Di Tommaso L, Baretti M, et al. Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy. 2016;8:1363-9.
24. Huffman BM, Kottschade LA, Kamath PS, et al. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: Natural progression and management. Am J Clin Oncol. 2017. https://doi. org/10.1097/COC.0000000000000374.
25. Lindros KO. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen Pharmacol. 1997;28:191-6.
26. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J. 1998;329(Pt 1):17-35.
27. Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: How to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2017. https://doi.org/10.1007/s10637-017-0484-6.
28. Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529-36.
29. Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol. 2017;41:134-7.